4553 — Towa Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Towa Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	110,384	154,900	165,615	208,859	227,934
Cost of Revenue
Gross Profit	50,646	65,452	70,186	72,714	81,383
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	90,844	137,411	144,103	205,685	204,980
Operating Profit	19,540	17,489	21,512	3,174	22,954
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	20,709	18,728	22,246	4,605	24,459
Provision for Income Taxes
Net Income After Taxes	14,503	13,958	15,915	2,201	16,173
Net Income Before Extraordinary Items
Net Income	14,503	13,958	15,915	2,201	16,173
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	14,496	13,944	15,912	2,201	16,173
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	228	321	298	172	340
Dividends per Share
Special Dividends per Share